ERBB2 and neoplasm: Preclinical studies have indicated that CAR-M therapy can effectively reduce the tumor burden in murine models of breast cancer by targeting endothelial growth factor receptor-2 (VEGFR2) [187], HER-2 [188], or other receptors, paving the way for clinical translation.